Thursday, August 18, 2022 5:01:16 PM
You assume that the 2-73 treatment for AD is far better than the trial data supports.
Yes there have been some very good results from a few that recovered significant losses. The painter, the piano player etc.
There were also a lot of subjects that continued to decline albeit at a reduced rate and some that quit declining. Those results aren't going to cause "the existing supply chain" to fall apart.
2-73 is very likely to become the SOC for AD and other CNS diseases. As much as I hate to echo this line, it is not a magic bullet. 2-73 is a major improvement in the almost nonexistent SOC and represents a paradigm shift in the treatment of CNS diseases. That is huge and should make Anavex investors a lot of money as well as improve the lives of many folks that have a very bleak future.
None of the RETT girls are going to be getting high school diplomas after taking 2-73. They will be improved from where they currently are and that is very good thing. We don't know the current AD trial results, even if they are much better than the previous AD trial there will still be a lot of people that will still have to deal with AD cognitive issues. What will be changed is there will be hope for some percentage of people to recover some lost functioning. There will be hope for some to halt the decline. This represents hope where there presently is none. That is a very big deal.
Yes there have been some very good results from a few that recovered significant losses. The painter, the piano player etc.
There were also a lot of subjects that continued to decline albeit at a reduced rate and some that quit declining. Those results aren't going to cause "the existing supply chain" to fall apart.
2-73 is very likely to become the SOC for AD and other CNS diseases. As much as I hate to echo this line, it is not a magic bullet. 2-73 is a major improvement in the almost nonexistent SOC and represents a paradigm shift in the treatment of CNS diseases. That is huge and should make Anavex investors a lot of money as well as improve the lives of many folks that have a very bleak future.
None of the RETT girls are going to be getting high school diplomas after taking 2-73. They will be improved from where they currently are and that is very good thing. We don't know the current AD trial results, even if they are much better than the previous AD trial there will still be a lot of people that will still have to deal with AD cognitive issues. What will be changed is there will be hope for some percentage of people to recover some lost functioning. There will be hope for some to halt the decline. This represents hope where there presently is none. That is a very big deal.
If investing was easy, everyone would be rich by now.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
